GAJ - Fourth International Workshop on HIV Persistence during Therapy





		Fourth International Workshop on HIV Persistence during Therapy Click here to view the complete abstract book Selected Slide Presentations Click on the links below to view presentations. ANIMALS MODELS & RESERVOIRS Reservoirs & Latency in Animal Models Anding Shen; Calvin College, Grand Rapids, USA Macrophage Reservoirs in Animal Models Mauro Magnani; University of Urbino, Urbino, Italy The Large Intestine as a Major Reservoir for SIV Persistence and Replication in Long Term Non-progressing Macaques Ronald Veazey; Tulane National Primate Research Center, Covington, USA Evolution and Persistence of Virus during Suppressive Antiretroviral Therapy in Macaques Infected with RT-SHIVmne Zandrea Ambrose; University of Pittsburgh School of Medicine, Pittsburgh, USA CELLULAR BIOLOGY & RESERVOIRS Molecular Mechanisms of HIV Latency José Alcami; Instituto de Salud Carlos III, Madrid, Spain The HIV Vif Protein Antagonizes the Effect of the Host Cell Innate Immunity Enzyme PRMT-6 Mark Wainberg; McGill University AIDS Centre, Montreal, Canada Epigenetic and Non-epigenetic Mechanisms Controlling HIV Entry and Exit from Latency Jonathan Karn; Case Western Reserve University, Cleveland, USA Roles of NFAT, Cell Division and IL-7 Stimulation on HIV-1 Reactivation from Latency in Primary Memory T Cells Alberto Bosque; University of Utah, Salt Lake City, USA Cellular Levels of HIV-1 Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome Alexander Pasternak; University of Amsterdam, Amsterdam, the Netherlands VIROLOGY, IMMUNOLOGY & RESERVOIRS HIV Tropism and Reservoirs Pierre Delobel; INSERM, Toulouse, France Immunological Mechanisms Involved in the Establishment and Persistence of the Reservoir Nicolas Chomont; Université de Montréal, Montreal, Canada HIV-1 Latency in CD34+ Hematopoietic Progenitor Cells Adewunmi Onafuwa-Nuga; University of Michigan, Ann Arbor, USA PHARMACOLOGY, INTENSIFICATION & RESERVOIRS Use of Therapeutic Intensification to Probe the Source of Residual Viremia in HIV-infected Patients on Suppressive Therapy John Coffin; Tufts University, Boston, USA Enhancing ARV Delivery to Sanctuary Sites Vinod Labhasetwar; Lerner Research Institute, Cleveland, USA Tackling HIV Reservoirs with Common-y Chain Cytokines (IL-2, IL-7, GM-CSF). Lessons Learned and Perspectives Guido Poli; San Raffaele Scientific Institute, Milano, Italy Maraviroc Cerebrospinal Fluid Concentrations in HIV-1 Infection Aylin Yilmaz; Sahlgrenska University Hospital, Gothenburg, Sweden Enhancing the Transversing Efficiency and Efficacy of the Anti Retroviral Drug ?Saquinavir? using Nanotechnology: Implications for Nanotherapeutics in Neuro-Aids Supriya Mahajan; State University of New York at Buffalo, Buffalo, USA CLINICAL IMPLICATIONS OF COMPARTMENTS & RESERVOIRS Is the Genital Tract a Distinct Compartment? Pietro Vernazza; Kantonsspital, St. Gallen, Switzerland No Decay in HIV-infected Naive CD4+ T-cells Following Antiretroviral Therapy (ART): a Persistent Long Term Reservoir Sharon Lewin; Alfred Hospital, Melbourne, Australia RESEARCH PRESENTATIONS FROM FIRMS SUPPORTING THE MEETING Interest of Ultrasensitive Viral Load On behalf of Boheringer Ingelheim Jacques Izopet; Toulouse, France PRIMARY HIV INFECTION & ERADICATION ISSUES Purging the HIV-1 Reservoir through the Disruption of the PD-1 Pathway Sandrina Da Fonseca; Université de Montréal, Montréal, Canada Tissue Viral Dynamics in SIV Infected Macaques with Highly Active Antiretroviral Therapy (HAART) Olivier Bourry; GERHM-Inserm U625, Rennes, France An In Vitro System to Model HIV-1 Latency Fabio Romerio; Institute of Human Virology, Baltimore, USA Syndecan-1 Expression and Microbial Translocation in HIV-1 Infection Anthony Smith; University of Minnesota, Minneapolis, USA Ex Vivo, BIT225 Inhibits the Spread and Transfer of HIV-1 from the Infected Monocytes of HIV-1 Seropositive Individuals John Wilkinson; Biotron Limited, Sydney, Australia NEW THERAPEUTIC APPROACHES Killing of Latently HIV-infected Cells Yuntao Wu; George Mason University, USA ?Shock and Kill? Research to Combat HIV-1 Latency Andrea Savarino; Istituto Superiore di Sanità, Rome, Italy Correlation Between the Isoform Specificity of HDAC Inhibitors and their Ability to Reactivate Latent HIV-1 Infection Nicolas Sluis-Cremer; University of Pittsburgh, Pittsburgh, USA Novel Small Molecule Transcriptional Inhibitors of HIV-1 which Suppress Virus Production from Infected Cells Robert Buckheit; ImQuest BioSciences, Inc., Frederick, USA Increased HIV-specific Immunity in HIV-infected Individuals Vaccinated with a DNA Prime, rAd5 Boost Regimen Joe Casazza; VRC/NIAID/NIH, Bethesda, USA